Physician profile
Tracy A Scott
NPI 1760921696
$3,084.80
in general payments reported to CMS, 2019-2025
20 companies · $1,236 in 2025
The $1,236 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $431 · 2022: $200 · 2023: $301 · 2024: $916 · 2025: $1,236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,453.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $746.64 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $551.23 | 2023-2025 | |
| Novo Nordisk INC | $496.25 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $407.52 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Vanda Pharmaceuticals INC. | $149.84 | 2021-2023 | Hetlioz, Fanapt |
| Pfizer INC. | $125.53 | 2022-2025 | |
| Axsome Therapeutics, INC. | $106.29 | 2024-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $82.76 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $59.42 | 2021-2024 | Rexulti |
| Braeburn INC. | $59.18 | 2024-2025 | Brixadi |
| Glaxosmithkline, LLC. | $57.41 | 2022-2024 | Trelegy Ellipta, Arexvy |
| Antares Pharma, INC. | $46.67 | 2024-2025 | Xyosted |
| Exact Sciences Corporation | $44.95 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.02 | 2022-2023 | Jardiance |
| Indivior INC. | $32.21 | 2021-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $24.65 | 2025 | Neffy |
| Alkermes, INC. | $18.87 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $18.01 | 2021 | |
| Nevro Corp. | $15.30 | 2022 | |
| Genentech USA, INC. | $6.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.